恆地(00012.HK)紅磡「必嘉坊-曦匯」料短期上樓書 最快下周開售
恆地(00012.HK)紅磡重建項目「必嘉坊」內之Baker Circle One第一期今日正式命名為「必嘉坊-曦匯 Baker Circle-Dover」。
恆基物業代理營業(一)部總經理林達民表示,「必嘉坊」共設有9幢大樓,提供約2,800個住宅單位,將分3個階段推出,其中首階段Baker Circle One合共三期,第一期「必嘉坊-曦匯」位處機利士南路及必嘉街交界(近寶其利街),共設逾320個住宅單位,將提供開放式至最大三房間隔,實用面積由約200至570平方呎,並以一房戶型為主打,佔第一期單位逾五成。
他預計,項目將於短期內上載售樓說明書及開放示範單位,最快下周開售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.